Skip to main content

Table 3 Discontinuation due to medication

From: Effect of medications on prevention of secondary osteoporotic vertebral compression fracture, non-vertebral fracture, and discontinuation due to adverse events: a meta-analysis of randomized controlled trials

Comparison No. of participants (studies) RR (95% CI)
ZOL vs. Control 665 (1 RCT) 1.99 (0.76, 5.25)
ALN vs. Control 2750 (2 RCTs) 0.88 (0.64, 1.22)
RISE vs. Control 2707 (3 RCTs) 0.88 (0.69, 1.12)
Etidronate vs. Control 322 (3 RCTs) 0.40 (0.03, 5.48)
Ibandronate vs. Control
 2.5 mg/d & 20 mg alternatively 2929 (1 RCT) 0.90 (0.69, 1.18)
 0.5 mg & 1 mg per 3 months 2860 (1 RCT) 1.27 (0.97, 1.66)
PTH vs. Control 2215 (2 RCTs) 1.54 (1.11, 2.13)
 56.5 μg/w 578 (1 RCT) 1.80 (1.00, 3.24)
 20 μg/d 813 (1 RCT) 1.10 (0.62, 1.95)
 40 μg/d 824 (1 RCT) 1.82 (1.07, 3.10)
Denosumab vs. Control 956 (1 RCT) 0.75 (0.44, 1.27)
HRT vs. Control 79 (2 RCTs) 0.53 (0.17, 1.61)
ALN vs. Denosumab 717 (1 RCT) 0.79 (0.15, 4.02)
Romosozumab vs. Alendronate 4093 (1 RCT) 1.00 (0.58, 1.74)
RISE vs. Teriparatide 2070 (2 RCT) 0.75 (0.57, 1.00)
HRT vs. Etidronate 35 (1 RCT) 2.83 (0.33, 24.66)
  1. RR Relative Risk, ZOL Zoledronate, ALN Alendronate, RISE Risedronate, PTH Pamidronate, HRT Hormone replace therapy